Dates: July 12-15, 2026
Location: ExCeL London, UK
Organizer: Alzheimer's Association
Website: aaic.alz.org
The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of Alzheimer's and dementia researchers. AAIC 2026 brings together researchers from around the world to share the latest findings in Alzheimer's disease, dementia, and related neurodegenerative conditions.
|
|
| Dates |
July 12-15, 2026 |
| Location |
ExCeL London, UK |
| Time Zone |
British Summer Time (BST) |
| Website |
aaic.alz.org |
- Abstract Submission (Developing Topics): March 31 – April 11, 2026
- Early Bird Registration: May 15, 2026
- Preconferences/Educational Workshops: July 10-11, 2026
- Plenary Sessions: Daily keynotes from leading researchers
- Scientific Sessions: Multiple tracks covering basic science, clinical research, and therapeutics
- ISTAART Sessions: Professional development and networking sessions
- Poster Sessions: Interactive presentations from researchers worldwide
- Basic Science: Amyloid, tau, and emerging biomarker research
- Clinical Research: Treatment trials, prevention studies, and clinical outcomes
- Care and Support: Dementia care practices, quality of life, and support systems
- Risk Factors: Lifestyle, genetics, and environmental factors
AAIC 2026 features comprehensive coverage of therapeutic approaches for Alzheimer's disease and related dementias:
- Lecanemab (Leqembi): Real-world effectiveness data, ARIA management, long-term outcomes
- Donanemab: New analyses on amyloid removal rates, subpopulation responses
- GSK4527226 (AL101): Progranulin enhancer Phase 2 results
- Bispecific antibodies: Dual-targeting strategies for enhanced brain penetration
- Tau immunotherapies: Various epitopes in clinical development
- Blood-based biomarker validation studies
- Tau PET imaging advancements
- Combination biomarker panels
- Digital biomarker development
- Anti-amyloid antibody trials
- Anti-tau therapy results
- Prevention trial results
- Novel mechanism approaches
Major pharmaceutical companies typically present at AAIC:
- Biogen — Amyloid-targeting therapies
- Eli Lilly — Donanemab and other programs
- Roche — Gantenerumab and combination approaches
- Eisai — Lecanemab and next-generation therapies
- AbbVie — Tau and neuroinflammation programs
- Merck — BACE inhibitors and other approaches
Leading academic centers present their findings:
- University of Washington
- Massachusetts General Hospital
- University of Cambridge
- Karolinska Institute
- UCLA
- AAIC 2026 Official Website
- AAIC 2026 Program
- Alzheimer's Association